Serine/threonine protein kinase
From Proteopedia
(Difference between revisions)
| Line 113: | Line 113: | ||
*'''Chk10 (lymphocyte-oriented kinase)''' | *'''Chk10 (lymphocyte-oriented kinase)''' | ||
| - | **[[2j7t]], [[4aot]], [[4equ]], [[5ajq]], [[5owq]], [[5owr]] – hChk10 kinase domain + inhibitor<br /> | + | **[[2j7t]], [[4aot]], [[4equ]], [[5ajq]], [[5owq]], [[5owr]], [[6eim]], [[6gtt]] – hChk10 kinase domain + inhibitor<br /> |
*'''Chk11''' | *'''Chk11''' | ||
| Line 133: | Line 133: | ||
*Plk1 Pbd complex with polypeptide | *Plk1 Pbd complex with polypeptide | ||
| - | **[[1umw]], [[2ojx]], [[3bzi]], [[3c5l]], [[3rq7]], [[4dfw]], [[4whl]], [[4whk]], [[4whh]], [[4rcp]], [[4o6w]], [[4o56]], [[5dms]], [[5dmv]], [[5dnj]] – Plk1 | + | **[[1umw]], [[2ojx]], [[3bzi]], [[3c5l]], [[3rq7]], [[4dfw]], [[4whl]], [[4whk]], [[4whh]], [[4rcp]], [[4o6w]], [[4o56]], [[5dms]], [[5dmv]], [[5dnj]] – Plk1 + peptide<br /> |
| - | **[[3hik]], [[3fvh]], [[3p2z]], [[3p34]], [[3p35]], [[3p36]], [[3p37]], [[3q1i]], [[4e67]], [[4e9c]], [[4e9d]], [[4hab]], [[4hy2]], [[4o9w]], [[4x9r]], [[4x9v]], [[4x9w]], [[5j19]] – Plk1 | + | **[[3hik]], [[3fvh]], [[3p2z]], [[3p34]], [[3p35]], [[3p36]], [[3p37]], [[3q1i]], [[4e67]], [[4e9c]], [[4e9d]], [[4hab]], [[4hy2]], [[4o9w]], [[4x9r]], [[4x9v]], [[4x9w]], [[5j19]] – Plk1 + phosphopeptide<br /> |
| - | **[[1q4k]] – Plk1 | + | **[[1q4k]] – Plk1 (mutant) + phosphopeptide<br /> |
| - | **[[2v5q]] – Plk1 | + | **[[2v5q]] – Plk1 + design ankyrin repeat protein<br /> |
**[[4lkl]] – hChk Plk1 + PL-55 <br /> | **[[4lkl]] – hChk Plk1 + PL-55 <br /> | ||
**[[4lkm]] – hChk Plk1 + PL-74 <br /> | **[[4lkm]] – hChk Plk1 + PL-74 <br /> | ||
| + | **[[6ax4]] – hChk Plk1 + histidine cyclized macrocycle <br /> | ||
| + | **[[5x3s]] – mPlk1 + phosphopeptide<br /> | ||
*Plk1 Pbd complex with small molecule inhibitor | *Plk1 Pbd complex with small molecule inhibitor | ||
| - | **[[4h71]], [[4hco]], [[5ta6]], [[5ta8]] – Plk1 | + | **[[4h71]], [[4hco]], [[5ta6]], [[5ta8]] – Plk1 + inhibitor<br /> |
| - | **[[2rku]] – Plk1 | + | **[[2rku]] – Plk1 (mutant) + inhibitor<br /> |
| - | **[[3db6]], [[3db8]], [[3dbc]], [[3dbd]], [[3dbe]], [[3dbf]] – zfPlk1 | + | **[[3db6]], [[3db8]], [[3dbc]], [[3dbd]], [[3dbe]], [[3dbf]] – zfPlk1 (mutant) + inhibitor – zebra fish<br /> |
*Plk1 catalytic domain | *Plk1 catalytic domain | ||
| Line 158: | Line 160: | ||
*'''Plk2''' | *'''Plk2''' | ||
| - | **[[4i5m]], [[4i5p]], [[4i6f]], [[4i6h]] – hChk Plk2 kinase domain (mutant) + inhibitor <br /> | + | **[[4i5m]], [[4i5p]], [[4i6b]], [[4i6f]], [[4i6h]] – hChk Plk2 kinase domain (mutant) + inhibitor <br /> |
**[[4xb0]], [[4rs6]] – hChk Plk2 Pbd <br /> | **[[4xb0]], [[4rs6]] – hChk Plk2 Pbd <br /> | ||
| Line 174: | Line 176: | ||
**[[4yyp]], [[5lhz]] – hChk Plk4 Pb3 domain + Scl-interrupting locus protein <br /> | **[[4yyp]], [[5lhz]] – hChk Plk4 Pb3 domain + Scl-interrupting locus protein <br /> | ||
**[[4nk7]], [[4g7n]], [[5lhx]] – Chk Plk4 Pbd domain – ''Drosophila melanogaster''<br /> | **[[4nk7]], [[4g7n]], [[5lhx]] – Chk Plk4 Pbd domain – ''Drosophila melanogaster''<br /> | ||
| - | |||
| - | *'''Chk15 (Aurora kinase a)''' | ||
| - | |||
| - | **[[4o0s]] – hChk15 kinase domain <br /> | ||
| - | **[[4bn1]], [[4o0w]], [[4o0u]] – hChk15 kinase domain (mutant) <br /> | ||
| - | **[[4byi]], [[4byj]], [[4jai]], [[4jaj]], [[3w10]], [[3w16]], [[3w18]], [[3w2c]], [[4uzh]], [[4uzd]], [[4uyn]], [[4zs0]], [[4ztq]], [[4ztr]], [[4zts]], [[5aad]], [[5aae]], [[5aag]], [[5dr6]], [[5dr9]], [[5dt0]], [[5ew9]], [[5obr]], [[5one]] – hChk15 kinase domain + inhibitor <br /> | ||
| - | **[[4jbo]], [[4jbp]], [[4jbq]], [[4prj]], [[5dpv]] – hChk15 kinase domain (mutant) + inhibitor <br /> | ||
| - | **[[5dn3]], [[5dos]], [[5dt4]], [[5obj]] – hChk15 kinase domain + ATP + inhibitor <br /> | ||
| - | **[[5dr2]] – hChk15 kinase domain (mutant) + ATP + inhibitor <br /> | ||
| - | **[[5dnr]], [[5drd]], [[5dt3]] – hChk15 kinase domain + ATP <br /> | ||
| - | **[[5g1x]] – hChk15 kinase domain (mutant) + N-Myc <br /> | ||
| - | **[[5l8j]], [[5l8k]], [[5l8l]] – hChk15 kinase domain (mutant) + new antigen receptor variable domain <br /> | ||
| - | **[[5lxm]] – hChk15 kinase domain (mutant) + Targeting protein for XKLP2 <br /> | ||
*'''Chk16''' | *'''Chk16''' | ||
Revision as of 23:06, 17 September 2018
| |||||||||||
3D structures of serine/threonine protein kinase
Updated on 17-September-2018
References
- ↑ Bartek J, Lukas J. Chk1 and Chk2 kinases in checkpoint control and cancer. Cancer Cell. 2003 May;3(5):421-9. PMID:12781359
- ↑ Ducat D, Zheng Y. Aurora kinases in spindle assembly and chromosome segregation. Exp Cell Res. 2004 Nov 15;301(1):60-7. PMID:15501446 doi:http://dx.doi.org/10.1016/j.yexcr.2004.08.016
- ↑ Takai N, Hamanaka R, Yoshimatsu J, Miyakawa I. Polo-like kinases (Plks) and cancer. Oncogene. 2005 Jan 10;24(2):287-91. PMID:15640844 doi:http://dx.doi.org/10.1038/sj.onc.1208272
- ↑ Dummler B, Ohshiro K, Kumar R, Field J. Pak protein kinases and their role in cancer. Cancer Metastasis Rev. 2009 Jun;28(1-2):51-63. doi: 10.1007/s10555-008-9168-1. PMID:19165420 doi:http://dx.doi.org/10.1007/s10555-008-9168-1
- ↑ Forde JE, Dale TC. Glycogen synthase kinase 3: a key regulator of cellular fate. Cell Mol Life Sci. 2007 Aug;64(15):1930-44. PMID:17530463 doi:http://dx.doi.org/10.1007/s00018-007-7045-7
- ↑ Brose MS, Volpe P, Feldman M, Kumar M, Rishi I, Gerrero R, Einhorn E, Herlyn M, Minna J, Nicholson A, Roth JA, Albelda SM, Davies H, Cox C, Brignell G, Stephens P, Futreal PA, Wooster R, Stratton MR, Weber BL. BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res. 2002 Dec 1;62(23):6997-7000. PMID:12460918
- ↑ Antony R, Emery CM, Sawyer AM, Garraway LA. C-RAF mutations confer resistance to RAF inhibitors. Cancer Res. 2013 Aug 1;73(15):4840-51. doi: 10.1158/0008-5472.CAN-12-4089. Epub, 2013 Jun 4. PMID:23737487 doi:http://dx.doi.org/10.1158/0008-5472.CAN-12-4089
- ↑ Laplante M, Sabatini DM. mTOR signaling in growth control and disease. Cell. 2012 Apr 13;149(2):274-93. doi: 10.1016/j.cell.2012.03.017. PMID:22500797 doi:http://dx.doi.org/10.1016/j.cell.2012.03.017
- ↑ Ravindran R, Loebbermann J, Nakaya HI, Khan N, Ma H, Gama L, Machiah DK, Lawson B, Hakimpour P, Wang YC, Li S, Sharma P, Kaufman RJ, Martinez J, Pulendran B. The amino acid sensor GCN2 controls gut inflammation by inhibiting inflammasome activation. Nature. 2016 Mar 24;531(7595):523-7. doi: 10.1038/nature17186. Epub 2016 Mar 16. PMID:26982722 doi:http://dx.doi.org/10.1038/nature17186
- ↑ Atilla-Gokcumen GE, Di Costanzo L, Meggers E. Structure of anticancer ruthenium half-sandwich complex bound to glycogen synthase kinase 3beta. J Biol Inorg Chem. 2010 Sep 7. PMID:20821241 doi:10.1007/s00775-010-0699-x

